## 32-4186: Recombinant Human Myeloid Cell Leukemia Sequence 1

$\begin{array}{ll} & \text { Myeloid cell leukemia sequence } 1 \text { (BCL2-related), induced myeloid leukemia cell differentiation protein } \\ \text { Alternative } & \text { Mcl-1,myeloid cell leukemia ES,Bcl-2-related protein EAT/mcl1,Bcl-2-like protein 3,MCL1- } \\ \text { Name: } & \text { ES,MCL1S,mcl1/EAT,BCL2L3,MCL1L. }\end{array}$

## Description

Source : E.coli. MCL1 Human Recombinant produced in E. coli is a single polypeptide chain containing 347 amino acids (1-327) and having a molecular mass of 37.2 kDa .MCL1 is fused to a 20 amino acid His-tag at N-terminus \& purified by proprietary chromatographic techniques. MCL1 is a member of the Bcl-2 family. MCL1 takes part in the control of apoptosis against cell existence, and in the preservation of viability but not of proliferation. Alternative splicing happens at this locus and two transcript variants encoding different isoforms are known. Isoform 1 is the longer gene product and it increases cell existence by inhibiting apoptosis. Isoform 2 is a shorter gene product which indorses apoptosis and is death-inducing.

## Product Info

| Amount : | $10 \mu \mathrm{~g}$ |
| :---: | :---: |
| Purification : | Greater than $90 \%$ as determined by SDS-PAGE. |
| Content : | The MCL1 solution $(0.25 \mathrm{mg} / 1 \mathrm{ml})$ contains 20 mM Tris- HCl buffer ( pH 8.0 ), $0.2 \mathrm{M} \mathrm{NaCl}, 2 \mathrm{mM}$ DTT and $20 \%$ glycerol. |
| Storage condition : | Store at $4^{\circ} \mathrm{C}$ if entire vial will be used within 2-4 weeks. Store, frozen at $-20^{\circ} \mathrm{C}$ for longer periods of time. For long term storage it is recommended to add a carrier protein ( $0.1 \%$ HSA or BSA).Avoid multiple freeze-thaw cycles. |
| Amino Acid : | MGSSHHHHHH SSGLVPRGSH MFGLKRNAVI GLNLYCGGAG LGAGSGGATR PGGRLLATEK EASARREIGG GEAGAVIGGS AGASPPSTLT PDSRRVARPP PIGAEVPDVT ATPARLLFFA PTRRAAPLEE MEAPAADAIM SPEEELDGYE PEPLGKRPAV LPLLELVGES GNNTSTDGSL PSTPPPAEEE EDELYRQSLE IISRYLREQA TGAKDTKPMG RSGATSRKAL ETLRRVGDGV QRNHETAFQG MLRKLDIKNE DDVKSLSRVM IHVFSDGVTN WGRIVTLISF GAFVAKHLKT INQESCIEPL AESITDVLVR TKRDWLVKQR GWDGFVEFFH VEDLEGG. |



